Titlebook: Introduction to Biologic and Biosimilar Product Development and Analysis; Karen M. Nagel Book 2018 American Association of Pharmaceutical

只看該作者 · 發(fā)表于 2025-3-21 16:47:25

書目名稱Introduction to Biologic and Biosimilar Product Development and Analysis影響因子(影響力)

書目名稱Introduction to Biologic and Biosimilar Product Development and Analysis影響因子(影響力)學(xué)科排名

書目名稱Introduction to Biologic and Biosimilar Product Development and Analysis網(wǎng)絡(luò)公開度

書目名稱Introduction to Biologic and Biosimilar Product Development and Analysis網(wǎng)絡(luò)公開度學(xué)科排名

書目名稱Introduction to Biologic and Biosimilar Product Development and Analysis被引頻次

書目名稱Introduction to Biologic and Biosimilar Product Development and Analysis被引頻次學(xué)科排名

書目名稱Introduction to Biologic and Biosimilar Product Development and Analysis年度引用

書目名稱Introduction to Biologic and Biosimilar Product Development and Analysis年度引用學(xué)科排名

書目名稱Introduction to Biologic and Biosimilar Product Development and Analysis讀者反饋

書目名稱Introduction to Biologic and Biosimilar Product Development and Analysis讀者反饋學(xué)科排名

只看該作者 · 發(fā)表于 2025-3-21 21:50:42

Therapeutic Proteins,duction of recombinant insulin in 1982. With the advent of recombinant technology in manufacturing, the reliance on animal and human sources diminished, safety and supply of proteins and peptides increased, and costs decreased. This chapter will focus on the considerations specific to formulation, d

只看該作者 · 發(fā)表于 2025-3-22 02:20:39

只看該作者 · 發(fā)表于 2025-3-22 06:49:35

Analysis and Regulation of Biologics, Including Biosimilars,2017. EvaluatePharma predicts that by 2024, 9 of the top 15 pharmaceuticals by sales in the United States, and 10 worldwide will be monoclonal antibodies or fusion proteins. Many of these products have patents that have already or soon will expire. Due to the complex nature of biologics, they are ty

只看該作者 · 發(fā)表于 2025-3-22 12:36:49

只看該作者 · 發(fā)表于 2025-3-22 14:53:57

AAPS Introductions in the Pharmaceutical Scienceshttp://image.papertrans.cn/i/image/473468.jpg

只看該作者 · 發(fā)表于 2025-3-22 18:43:10

只看該作者 · 發(fā)表于 2025-3-23 00:32:29

只看該作者 · 發(fā)表于 2025-3-23 02:41:27

Book 2018ustry who are switching focus from small molecules to biologics processing, analysis, and delivery.?? In order to maintain a limited focus, Introduction to Biologic and Biosimilar Product Development and Analysis,?will deal only with peptides, proteins and monoclonal antibodies..?.

只看該作者 · 發(fā)表于 2025-3-23 09:13:37

https://doi.org/10.1007/978-3-319-98428-5recombinant DNA technology; Therapeutic Proteins; Therapeutic antibodies; Biologics analysis; biologics

		自動登錄	找回密碼
密碼			To register

關(guān)于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務(wù)流程	影響因子官網(wǎng)	吾愛論文網(wǎng)	大講堂	北京大學(xué)	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點評	投稿經(jīng)驗總結(jié)	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學(xué)	Yale Uni.	Stanford Uni.
\|Archiver\|手機版\|小黑屋\| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-24 01:50
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved